Moberg Pharma AB (publ)
MOB.ST · Health Technology · Pharmaceuticals: Major · SE
12 employees · mobergpharma.se
About
Moberg Pharma AB develops and commercializes medical products for skin diseases and pain, including Emtrix/Nalox for fungal or psoriatic nail damage, Kerasal for dry feet, and Kaprolac for various skin and scalp issues. The company generates revenue through its OTC brands in the U.S. and collaborates with partners like Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma, and Zelmic AB to distribute products across more than 35 countries. It operates through Alterna LLC in certain markets and has two phase II development projects, MOB-15 for nail fungus and Limtop for actinic keratosis, basalioma, and genital warts. The company sells its products directly to consumers via OTC channels in the U.S. and through partnerships with pharmaceutical distributors in international markets. Its primary customer segments include patients seeking treatments for skin conditions and healthcare providers prescribing these products. Moberg Pharma’s revenue streams are derived from product sales, with OTC brands representing a key commercial segment in the U.S. market.
Annual results
Reported figures, SEK · revenue up 44.4% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 13.0M | -27.0M | -207.7% | — |
| 2024 | 9.0M | -255M | -2833.3% | — |
| 2023 | 273M | -21.0M | -7.7% | — |
| 2022 | — | -15.0M | — | — |
| 2021 | 209M | -16.0M | -7.7% | — |
MOB.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Moberg Pharma AB (publ) are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.